Lymphoma | What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma

Featuring an interview with Dr Gilles Salles, including the following topics:

• Epigenetic modifications and the role of EZH2 in the pathobiology of follicular lymphoma (FL) (0:00)
• Natural history of FL and current treatment landscape in the first-line setting (5:20)
• Testing approaches for the detection of EZH2 mutations (14:37)
• Mechanism of action of the EZH inhibitors tazemetostat and valemetostat (18:31)
• Tazemetostat monotherapy as treatment for relapsed/refractory FL (20:58)
• Ongoing evaluation of novel treatment approaches with tazemetostat for FL and other lymphomas (25:31)
• Approved indications for tazemetostat for wild-type FL and FL with EZH2 mutations; sequencing of tazemetostat with bispecific antibodies and CAR T-cell therapy (34:07)
• Available clinical data with the novel dual EZH1/EZH2 inhibitor valemetostat (42:37)
• Personal experience with CAR T-cell therapy and perspectives on possible underlying reasons for the development of T-cell lymphoma in patients receiving this treatment (44:35)
• Management of FL in patients who experience relapse within 24 months of receiving treatment (POD24) (48:25)
• Myths or misperceptions associated with tazemetostat and other therapies approved in the relapsed FL setting (52:15)
• Perspectives on the future treatment landscape of FL (54:29)

CME information and select publications